We are live on
!
Find out more
Handelsbanken Fonder Portfolio holdings
AUM
$35.1B
1-Year Est. Return
47.76%
This Fund
S&P 500
This Quarter
Est. Return
+2.36%
1 Year Est. Return
+47.76%
3 Year Est. Return
+137.96%
5 Year Est. Return
+170.36%
10 Year Est. Return
+934.7%
AUM
$26.2B
AUM Growth
+$914M
(+3.6%)
Cap. Flow
+$1.01B
Cap. Flow
% of AUM
3.87%
Top 10 Holdings %
Top 10 Hldgs %
32.55%
Holding
1,591
New
69
Increased
817
Reduced
431
Closed
49
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$107M |
| 2 |
EXL Service
EXLS
|
+$72M |
| 3 |
Apple
AAPL
|
+$64.3M |
| 4 |
Synopsys
SNPS
|
+$56.8M |
| 5 |
ServiceNow
NOW
|
+$54.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Halozyme
HALO
|
+$74.5M |
| 2 |
Vertex Pharmaceuticals
VRTX
|
+$53.5M |
| 3 |
Edwards Lifesciences
EW
|
+$45M |
| 4 |
Abbott
ABT
|
+$40.3M |
| 5 |
Rockwell Automation
ROK
|
+$39.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 37.4% |
| 2 | Healthcare | 16.63% |
| 3 | Financials | 12.04% |
| 4 | Communication Services | 9.47% |
| 5 | Industrials | 8.26% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1276
NCR Voyix
VYX
$1.17B
| $515K | ﹤0.01% |
37,204
| – | – |
|
1277
Celanese
CE
$4.86B
| $514K | ﹤0.01% |
7,425
-800
| -10% | -$76.9K |
|
1278
Evertec
EVTC
$1.91B
| $514K | ﹤0.01% |
14,900
+2,000
| +16% | +$68.6K |
|
1279
Addus HomeCare
ADUS
$2.2B
| $512K | ﹤0.01% |
4,083
+600
| +17% | +$75.8K |
|
|
PPBI
1280
DELISTED
Pacific Premier Bancorp
PPBI
| $511K | ﹤0.01% |
20,523
+3,000
| +17% | +$79.5K |
|
1281
LiveRamp
RAMP
$2.31B
| $509K | ﹤0.01% |
16,767
+3,200
| +24% | +$89.5K |
|
1282
Park National Corp
PRK
$3.75B
| $508K | ﹤0.01% |
2,965
| – | – |
|
1283
The Bancorp
TBBK
$2.82B
| $505K | ﹤0.01% |
9,600
| – | – |
|
1284
10x Genomics
TXG
$7.58B
| $505K | ﹤0.01% |
35,200
+7,000
| +25% | +$110K |
|
|
INFN
1285
DELISTED
Infinera Corporation Common Stock
INFN
| $505K | ﹤0.01% |
76,906
-6,500
| -8% | -$43.3K |
|
1286
Genworth Financial
GNW
$3.77B
| $504K | ﹤0.01% |
72,090
-3,700
| -5% | -$26.6K |
|
1287
Quaker Houghton
KWR
$2.95B
| $504K | ﹤0.01% |
3,579
+500
| +16% | +$78.9K |
|
1288
Brady Corp
BRC
$4.43B
| $503K | ﹤0.01% |
6,809
| – | – |
|
1289
Materion
MTRN
$5.88B
| $501K | ﹤0.01% |
5,066
+900
| +22% | +$97.8K |
|
1290
NBT Bancorp
NBTB
$2.79B
| $501K | ﹤0.01% |
10,495
+1,200
| +13% | +$57.1K |
|
1291
TAL Education Group
TAL
$6.43B
| $501K | ﹤0.01% |
50,000
| – | – |
|
|
AIV
1292
Aimco
AIV
$379M
| $499K | ﹤0.01% |
54,948
| – | – |
|
1293
Compass
COMP
$10.2B
| $499K | ﹤0.01% |
85,300
+37,900
| +80% | +$240K |
|
1294
First Merchants
FRME
$2.72B
| $499K | ﹤0.01% |
12,516
| – | – |
|
1295
MasterBrand
MBC
$1.89B
| $498K | ﹤0.01% |
34,100
+1,600
| +5% | +$27.3K |
|
1296
Provident Financial Services
PFS
$3.26B
| $498K | ﹤0.01% |
26,374
+8,700
| +49% | +$172K |
|
1297
Recursion Pharmaceuticals
RXRX
$1.78B
| $498K | ﹤0.01% |
73,600
+4,100
| +6% | +$27.6K |
|
1298
Live Nation Entertainment
LYV
$43.3B
| $493K | ﹤0.01% |
3,807
+755
| +25% | +$95.1K |
|
1299
Wendy's
WEN
$1.65B
| $493K | ﹤0.01% |
30,257
-3,200
| -10% | -$58.4K |
|
|
JBGS
1300
JBG SMITH
JBGS
$692M
| $490K | ﹤0.01% |
31,900
+3,400
| +12% | +$56.9K |
|
Similar funds
GAM
Handelsbanken Fonder's Q4 2024 Portfolio in Review
As of Q4 2024, Handelsbanken Fonder held 1,591 positions worth $26.2B, up 3.6% from $25.3B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
Handelsbanken Fonder deployed $1.01B of net new capital in Q4 2024, opening 69 new positions and adding to 817 existing holdings. Its largest new stake was GE Vernova: 105,537 shares worth $34.7M.
By sector, the portfolio is most concentrated in Technology at 37% of assets, up from 35% a quarter earlier, followed by Healthcare and Financials.
On the sell side, the largest reduction was Halozyme, an estimated $74.5M trimmed.
- Handelsbanken Fonder's largest Q4 2024 buy was GE Vernova: 105,537 shares worth $34.7M.
- Handelsbanken Fonder added most to Microsoft in Q4 2024, an estimated $107M increase.
- Handelsbanken Fonder's biggest Q4 2024 reduction was Halozyme, cutting an estimated $74.5M.
- Handelsbanken Fonder fully exited BeOne Medicines Ltd in Q4 2024, selling an estimated $5.92M.
- Handelsbanken Fonder's ten largest holdings make up 33% of its $26.2B portfolio in Q4 2024.
- Handelsbanken Fonder opened 69 new positions and closed 49 in Q4 2024.
- Handelsbanken Fonder's portfolio value rose 3.6% quarter-over-quarter to $26.2B.
Based on Handelsbanken Fonder's 13F filing for Q4 2024, filed 3 Feb 2025.